Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma

Urology

Volumn 57, Issue 6, 2001, Pages 1179-1183

  Chang, Sam S ^a   Reuter, Victor E ^b   Heston, W D W ^b   Gaudin, Paul B ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIBODY; BIOLOGICAL MARKER; BIOTIN; DIAGNOSTIC AGENT; FORMALDEHYDE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E11; MONOCLONAL ANTIBODY PM2J004 5; PARAFFIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; STREPTAVIDIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER LOCALIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIODIAGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035008378     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)00983-9     Document Type: Article

References (24)

1. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res. 7:1987;927-936.
2. Israeli R.S., Powell C.T., Corr J.G., et al. Expression of the prostate-specific membrane antigen. Cancer Res. 54:1994;1807-1811.
3. Lopes A.D., Davis W.L., Rosenstraus M.J., et al. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 50:1990;6423-6429.
4. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 3:1997;81-85.
5. Wright G.L., Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol Oncol. 1:1995;18-28.
6. Liu H., Moy P., Kim S., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57:1997;3629-3634.
7. Chang S.S., Reuter V.E., Heston W.D.W., et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59:1999;3192-3198.
8. Leek J., Lench N., Maraj B., et al. Prostate-specific membrane antigen evidence for the existence of a second related human gene . Br J Cancer. 72:1995;583-588.
9. O'Keefe D.S., Su S.L., Bacich D.J., et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1443:1998;113-127.
10. Su S.L., Huang I.P., Fair W.R., et al. Alternatively spliced variants of prostate-specific membrane antigen RNA ratio of expression as a potential measurement of progression . Cancer Res. 55:1995;1441-1443.
11. Elgamal A.A., Troychak M.J., Murphy G.P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy analysis of 136 scans of 100 patients . Prostate. 37:1998;261-269.
12. Petronis J.D., Regan F., Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med. 23:1998;672-677.
13. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 159:1998;2041-2047.
14. Murphy G.P., Elgamal A.A., Su S.L., et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 83:1998;2259-2269.
15. Bostwick D.G., Pacelli A., Blute M., et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma a study of 184 cases . Cancer. 82:1998;2256-2261.
16. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 57:1997;2321-2324.
17. Wright G.L. Jr, Grob B.M., Haley C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 48:1996;326-334.
18. Troyer J.K., Beckett M.L., Wright G.L. Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 62:1995;552-558.
19. Grauer L.S., Lawler K.D., Marignac J.L., et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 58:1998;4787-4789.
20. Genega E.M., Hutchinson B., Reuter V.E., et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 11:2000;1186-1191.
21. Grob B.M., Schellhammer P.F., Brassil D.N., et al. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer. Urology. 44:1994;525-529.
22. Yam L.T., Janckila A.J., Lam W.K., et al. Immunohistochemistry of prostatic acid phosphatase. Prostate. 2:1981;97-107.
23. Bates R.J., Chapman C.M., Prout G.R. Jr, et al. Immunohistochemical identification of prostatic acid phosphatase correlation of tumor grade with acid phosphatase distribution . J Urol. 127:1982;574-580.
24. Ellis D.W., Leffers S., Davies J.S., et al. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol. 81:1984;279-284.